[Rimonabant--a panacea for patients with metabolic syndrome?].
Broncel
Marlena
M
Klinika Chorób Wewnetrznych z Oddzialem Farmakologii Klinicznej i Terapii Monitorowanej Uniwersytetu Medycznego w Lodzi.
Koziróg
Marzena
M
D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D063387:Cannabinoid Receptor Antagonists; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D000077285:Rimonabant; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D001786:Blood Glucose; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant